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Purpose: Behçet’s disease (BD) is a chronic inflammatory disease characterized by 
orogenital ulcers, skin and ocular lesions, in addition to articular, vascular, and neu-
rologic symptoms. Carpal tunnel syndrome (CTS), can also occur in BD patients 
secondary to inflammation in the connective tissues, vessels, and tendons, as well as 
nerve involvement in BD itself. However, reports of patients who have CTS in BD 
are rare. The aim of this study was to evaluate the clinical characteristics of CTS in 
BD patients. Materials and Methods: Retrospective analysis of the medical re-
cords of 1750 BD patients, and 14 (0.8%) BD patients who were diagnosed with 
CTS was performed at the BD Specialty Clinic of Severance Hospital. Patient de-
mographics, disease activity/severity for both diseases, and the clinical characteris-
tics of CTS in BD were recorded and analyzed. Results: All 14 BD patients with 
CTS were women. Twelve patients (85.7%) were diagnosed with active BD. The 
CTS was mild in 8 patients (57.2%), moderate in 3 patients (21.4%), and severe in 
3 patients (21.4%). Ten patients (71.4%) had BD prior to the diagnosis of CTS, and 
these 10 patients all had active BD. Conclusion: CTS can occur as a result of the in-
flammation associated with BD and can also be the presenting symptom of nerve 
involvement in BD. CTS can also develop as the initial symptom of BD. Therefore, 
a higher degree of suspicion should be maintained for CTS in patients with BD and 
vice versa; however, the exact relationship is uncertain.
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INTRODUCTION
Behçet’s disease (BD), a chronic systemic inflammatory disease, is characterized by 
recurrent oral and genital ulcers, cutaneous lesions, and recurrent uveitis. These ma-
jor findings can occasionally be accompanied by other manifestations, including 
gastrointestinal, articular, vascular, and neurologic involvement.1 Neurologic in-
volvement has been reported to occur in 2.2% to 49% of BD patients2-4 and is one 
of the major causes of morbidity in BD.5 Although central nervous system involve-
ment is not infrequent in BD, and symptoms such as headache and cognitive and 
behavioral changes can occur in BD patients, involvement of the peripheral nervous 
system is relatively rare.3,4,6-8 Only a few cases of peripheral neuropathy and myopa-
thy in BD patients have been reported in the literature.3,9 However, according to re-
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considered to have active disease. The clinical severity of the 
CTS was assessed by the clinical symptoms and was classi-
fied as mild, moderate, and severe according to the degree of 
paresthesia, numbness/pain, and associated muscle weakness 
as suggested by the British Society for Surgery of the Hand 
in 2011.18 
Statistical analysis
Analysis was performed using the Statistical Package for the 
Social Sciences version 18.0 (SPSS Inc., Chicago, IL, USA). 
Differences were considered statistically significant when 
the p-value was less than 0.05.
RESULTS
 
In our study, all 14 BD patients who had CTS were women, 
with a mean age of 54.1±8.3 years (range, 45 to 71 years) 
(Table 1). The overall frequency of CTS in our cohort was 
0.8%. The high percentage of women in our study may also 
be the result of the female predominance of BD in Korea.19 
The average patient age at the time of disease onset showed 
a slight difference between the 2 diseases, with onset at 31 
to 64 years for BD (mean 44.3±8.7 yr), and at 37 to 64 years 
for CTS (mean 48.1±8.3 yr). Ten patients (71.4%) had BD as 
the preceding disease, and 4 patients (28.6%) were diag-
nosed with CTS before being diagnosed with BD.
Twelve patients (85.7%) were diagnosed with active BD, 
and two patients (14.3%) were in a stable disease state with-
out any need for systemic medication. With respect to CTS, 
eight patients (57.2%) were diagnosed as mild, three patients 
were diagnosed (21.4%) as moderate, and three patients 
(21.4%) were diagnosed as severe. The three patients diag-
nosed with severe CTS all had atrophy of the thenar mus-
cle, and five patients (35.7%) had bilateral CTS. The clinical 
cent studies, peripheral neuropathy is not as uncommon 
among BD patients as previously thought.3,10-12 Articular 
manifestations are also relatively common, including sub-
acute to chronic synovitis.13
Carpal tunnel syndrome (CTS) is a representative mono-
neuropathy caused by entrapment of the median nerve in 
the carpal tunnel that affects approximately 0.9% to 1.2% of 
the general population.14 CTS can result from any cause that 
induces compression or irritation of the median nerve, in-
cluding synovitis, thickening of the tendon or flexor retinac-
ulum, fluid accumulation, or subsynovial connective tissue 
alterations.15 Patients with CTS typically present with pain 
and paresthesia/numbness (intermittent or constant) of the 
hand along the median nerve distribution. Atrophy and wast-
ing of the thenar muscle can also occur in the advanced stages.15
By definition, BD is associated with chronic, widespread 
inflammation and can be accompanied by peripheral nerve 
involvement; therefore, it is not surprising that CTS can oc-
casionally develop in BD patients. In this study, 14 BD pa-
tients who were also diagnosed with CTS were studied. As 
far as we know, there has been no detailed report discussing 
CTS in BD patients. The purpose of this study is to analyze 
the clinical presentation, characteristics, treatment, and prog-
nosis of CTS in BD.
MATERIALS AND METHODS
Patients
A retrospective review of the medical records of 1750 BD 
patients in search of people who were diagnosed with CTS 
between 2005 and 2012 at the BD Specialty Clinic of Sev-
erance Hospital was performed. The final study included 14 
BD patients diagnosed according to the criteria of the Inter-
national Study Group for BD and the revised criteria of the 
BD Research Committee of Japan.16,17 CTS was diagnosed 
based on the patients’ clinical presentation, physical exami-
nation (including Tinel’s sign and Phalen’s test), and nerve 
conduction studies (NCS) performed by a neurologist or an 
orthopedic surgeon.
Assessment of disease activity and severity
The disease activity of BD was assessed based on the pa-
tients’ presenting symptoms, using the diagnostic criteria of 
the International Study Group for BD and the revised crite-
ria of the BD Research Committee of Japan.16,17 Patients with 
≥2 major criteria with or without any minor criteria were 
Table 1. Demographics of the 14 Women with Behçet’s Dis-
ease and Carpal Tunnel Syndrome
Range Mean±SD
Age (yrs) 45‒71 54.1±8.3
Age of onset (yr)
BD 31‒64 44.3±8.7
CTS 37‒64 48.1±8.3
Duration of disease (mo)
BD 4‒480 154.9±153.5
CTS 3‒72 15.7±19.6
SD, standard deviation; yr, year; BD, Behçet’s disease; CTS, carpal tunnel 
syndrome; mo, month.
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based on physical and neurological examinations including 
Tinel’s sign and Phalen’s test. NCS and other radiologic 
studies were performed and confirmed by a specialist.
The overall prevalence of CTS among BD patients was 
0.8% in this retrospective study. Previous reports suggest 
that the prevalence of CTS among the general population is 
0.9‒1.2%.14 Given the retrospective nature of the present in-
vestigation, there is a greater chance of underestimation of 
CTS among BD patients in our clinic. Further prospective 
study is required to determine a precise prevalence of CTS 
in BD and compare it with that of the general population. 
All BD patients with CTS in the present study were mid-
dle-aged or elderly females. These findings reflect the gener-
al epidemiology of CTS, which develops most commonly 
in patients between 45 and 65 years of age, with a male to 
female ratio of 1:3.22 In most patients, BD developed before 
the onset of CTS. The 10 patients who had BD prior to the 
diagnosis of CTS had an active disease state, suggesting the 
possibility of active inflammatory processes additionally af-
fecting CTS development. The remaining four patients were 
diagnosed with CTS before the diagnosis of BD.
In general, bilateral CTS occurs in approximately 55% to 
65% of cases.23 In this study, however, bilateral CTS oc-
curred in only 35.7% of patients. This unusually low percent-
age might again be a result of the small sample size and have 
included patients before the other hand was affected. Pa-
tients presenting with unilateral symptoms are at increased 
risk for the development of CTS on the other side and should 
be followed closely. In the present study, the dominant hand 
was affected in eight (88.9%) of nine patients who had uni-
lateral CTS. All five patients with bilateral CTS had the dom-
inant hand affected first.
According to our findings, there were no significant asso-
ciations between the disease activity of BD and the clinical 
severity of CTS or NCS findings of CTS. These results are 
similar to previous reports which also showed a lack of cor-
relation between the clinical findings of BD and electrophy-
siologic data.4,12,24 Although inflammation created by vascu-
litis-induced tissue damage and secretion of pro-inflamma-
tory cytokines are involved in the development of neurologic 
symptoms in BD, non-vascular, nerve-targeted pathologic 
reactions that may not always correlate with disease activity 
can also occur in BD.12,20 The lack of association between 
BD activity and NCS findings may be due to subclinical 
neurologic abnormalities or clinical alteration of the disease 
status.4 The two patients who had normal findings in NCS 
studies had a relatively short duration of CTS (3 months and 
features of the 14 patients are shown in Table 2.
CTS was diagnosed with NCS in 12 patients (85.7%). Two 
patients (14.3%) failed to show any changes on NCS and 
were diagnosed clinically with CTS. No significant associa-
tions were identified between the disease activity of BD and 
the severity of CTS or between the BD activity and the abili-
ty of NCS to detect CTS.
Colchicine was prescribed for 10 patients (71.4%) as the 
main therapeutic drug for BD. Non-steroidal anti-inflamma-
tory drugs (NSAIDs) were used in three patients (21.4%) for 
arthralgias or pain control; systemic corticosteroids were 
used in five patients (35.7%) for uveitis or acute symptom re-
lief. Anticoagulants were administered to one patient (7.1%) 
for venous thrombosis, and 5-aminosalicylic acid was pre-
scribed for two patients (14.3%) for gastrointestinal symp-
toms. Topical corticosteroids were available for all patients to 
help treat mucocutaneous ulcers.
For the treatment of CTS, NSAIDs were used in seven pa-
tients (50.0%) for pain control. Antidepressants or anti-epi-
leptic agents, such as benzodiazepines or gabapentin, were 
prescribed to help reduce neuropathic pain in three patients 
(21.4%). Three patients who were classified with severe CTS 
had surgical treatment to release the transverse carpal liga-
ment. Three other patients did not receive any treatment for 
CTS and were kept under observation only.
DISCUSSION
Although there have been some reports about peripheral neu-
ropathy in BD,3,10-12 no studies have focused on CTS in BD. 
Despite an obvious pathophysiologic relationship between 
BD and CTS with respect to disease characteristics, studies 
exploring the relationship between the two entities are lack-
ing. In this study, we retrospectively evaluated the medical 
records of 14 patients who had both BD and CTS.
BD, which can theoretically involve all sizes of vessels, 
causes chronic inflammation in various organ systems, re-
sulting in diverse clinical manifestations including mucocu-
taneous, ocular, gastrointestinal, neurologic, and articular 
symptoms.20,21 Therefore, BD patients can present with var-
ious joint symptoms and neurologic symptoms, such as joint 
pain or swelling, tingling sensations, and numbness. BD 
patients with such complaints undergo thorough history-tak-
ing and physical examinations and are referred to the rheu-
matology, orthopedic surgery, or neurology departments for 
further testing. In the present study, CTS was diagnosed 
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sporine A, azathioprine, and thalidomide) can have neuro-
logic side effects,30 the physician must be able to differentiate 
drug-induced complications from other peripheral neuropa-
thies such as CTS.
Although this study had a small sample size and lacked bi-
opsy results, it is meaningful in that it is the first description 
of the relationship between CTS and BD. CTS can be the pre-
senting symptom of neurologic involvement in BD, but it is 
more likely that “inflammation-prone” conditions of BD can 
result in CTS as an associated musculoskeletal symptom or 
can promote the effects of mechanical stressors. CTS can 
even represent the first symptom of BD. Therefore, it is im-
portant to maintain a high degree of suspicion for CTS when 
BD patients present with wrist pain, tingling sensations, or 
finger numbness. 
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